NCT01463891 2023-07-24Post-marketing Surveillance for the Clinical Safety and Effectiveness of Eribulin Mesylate in Patients With Inoperable or Recurrent Breast Cancer (Study HAL01S)Eisai Inc.Completed963 enrolled
NCT03437083 2019-01-25A Study to Investigate the Efficacy and Safety of Eribulin in Korean Breast Cancer ParticipantsEisai Inc.Completed340 enrolled